Summary of Key Points
The British newspaper The Financial Times has reported that AstraZeneca (with a market value of $250 billion) is in talks with Bristol-Myers Squibb (BMS, with a market value of $130 billion) about a potential merger. However, considering industry trends, the degree of business overlap, and past experiences, this deal seems illogical. Given that The Financial Times previously made an unfounded claim in 2023 about AstraZeneca’s plans to divest its Chinese operations, this latest rumor actually reflects the deep-seated concerns within the European pharmaceutical industry under the competitive pressure from China and the United States.
I. The “Golden Age” of Giant Mergers is Long Over – Cost Savings Have Become a Problem
From the 1990s to 2010, mergers among large pharmaceutical companies were the trend: AstraZeneca itself was formed by the merger of Swedish company Astra and British company Zeneca; Pfizer’s acquisition of Wyeth, and Merck’s acquisition of Schering-Plough also occurred during this period. The rationale behind these mergers was simple:
- Combining Strong Products: By merging companies with complementary product lines, they could create a more robust portfolio.
- Cost Savings: Eliminating duplicate departments (such as marketing and R&D teams) would immediately reduce expenses, which shareholders welcomed as tangible benefits.
But why aren’t companies doing this anymore? Because the actual returns have fallen far short of expectations:
- Integrating two large companies is extremely challenging, especially due to differences in management styles and cultural conflicts, often leading to internal strife.
- New drug development is crucial for pharmaceutical success. Mergers can lead to bureaucracy, which hinders R&D progress. What was once intended as a “powerful alliance” often results in mutual hindrance. Investors have learned their lesson and now avoid such mergers.
II. AstraZeneca and BMS: Too Much Business Overlap Makes a Merger Unfeasible
Even ignoring industry trends, these two companies are a poor match:
- Significant Core Business Overlap: Both companies generate most of their revenue from oncology drugs, and their products are very similar—BMS relies on PD-1 + CTLA-4 antibodies, while AstraZeneca uses PD-L1 + CTLA-4 (both core combinations in immunotherapy).
- Antitrust Concerns: Such a high degree of overlap will attract attention from antitrust authorities. Even if regulations allow it, keeping duplicate products is useless; selling them would be like wasting money on unnecessary burdens.
In short, what’s the point of spending a fortune to acquire a company with almost identical business?
III. Two “Absurd Rumors” Point to the Same Target – Why Does The Financial Times Always Focus on AstraZeneca?
This merger rumor is not the first time The Financial Times has made unfounded claims about AstraZeneca:
- In 2023, the newspaper reported that AstraZeneca was planning to divest its Chinese operations, which were once its second-largest market. However, AstraZeneca later reversed this decision and even repurchased its early-stage R&D assets in China.
- Both rumors were baseless, but AstraZeneca is the target because it is currently the largest pharmaceutical company in the UK and, along with GSK, supports the UK pharmaceutical industry.
IV. The “Survival Anxiety” of the European Pharmaceutical Industry – The True Behind-the-Scenes Story
The European pharmaceutical industry is no longer the dominant force it once was:
- US Competition: American biotech innovation is advancing rapidly, prompting European companies to shift their focus to the US and reduce investment in Europe.
- Chinese Threat: Chinese companies are producing a variety of innovative drugs at fast pace, gaining significant market share.
- Trump’s Policies: Under Trump’s administration, there were demands for pharmaceutical companies to produce in the US, putting European firms in a difficult position.
As part of Europe, British media’s focus on AstraZeneca reflects their anxiety about the future of the industry. They worry that AstraZeneca might either “abandon” its Chinese operations or “align itself with” the US, fearing that this would weaken Europe’s pharmaceutical competitiveness.
Conclusion
The rumor of a merger between AstraZeneca and BMS is likely unfounded, but it highlights the concerns of the European pharmaceutical industry. How these established companies can maintain their position in the face of competition from China and the US will be a key topic in the coming years.